VANTAGE is a monitored, prospective, multi-center, non-randomized, open-label interventional trial, sponsored by Boston Scientific. The study evaluates Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system (Vercise™ DBS) in Parkinson’s disease.

The objective of the VANTAGE study is to document patient outcomes including effectiveness, safety and health economic data of bilateral stimulation of the Subthalamic Nucleus (STN) using the implantable Vercise DBS System for the treatment of levodopa-responsive, moderate to severe idiopathic Parkinson’s disease.